Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01552356 · ClinicalTrials.gov registry record · Phase 1

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

A Phase 1 study of Solid Neoplasm, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
54
Enrollment target
2
Study locations

NCT01552356 is a Phase 1 study of Solid Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 54 participants, below the 939-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01552356, a Phase 1 study of Solid Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
54 participants
Enrollment target
2
Study locations

Study Summary

This phase I trial studies the side effects and the best dose of pazopanib hydrochloride in treating patients with solid tumors that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or does not respond to treatment (refractory). Pazopanib hydrochloride may prevent the growth of new blood vessels that tumors need to grow. Studying samples of blood in the laboratory from patients receiving pazopanib hydrochloride may help doctors learn more about the effects of the body on the drug. It may also help doctors understand how well patients respond to treatment.

Conditions Studied

Solid Neoplasm

Interventions

  • OTHER Laboratory Biomarker Analysis
  • OTHER Pharmacological Study
  • DRUG Pazopanib Hydrochloride

Study Locations (2)

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2012-03-19
Est. Completion 2026-03-19
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01552356

The ClinicalTrials.gov registry entry for NCT01552356 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 939-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (94% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01552356 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT01552356 about?

NCT01552356 is a clinical study titled "Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors". This phase I trial studies the side effects and the best dose of pazopanib hydrochloride in treating patients with solid tumors that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or does not respond to treatment (refractory). Pazopanib hyd...

What is the current status of trial NCT01552356?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2012-03-19. Estimated completion is 2026-03-19.

What conditions does trial NCT01552356 study?

This clinical trial studies the following conditions: Solid Neoplasm.

What interventions are being tested in trial NCT01552356?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Pazopanib Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT01552356?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01552356 being conducted?

This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Neoplasm

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.